As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Announcement: COVID-19 impact on peer review
The Microbiota-Gut Brain Axis
We are currently accepting submissions to a new cross-journal series, The Microbiota-Gut-Brain Axis.
In partnership with twelve other BMC journals, this series will bring together human and animal studies covering all aspects of the axis' role in health and disease, including Alzheimer's.
Announcing the launch of In Review
In partnership with Research Square, Alzheimer's Research & Therapy is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Read more about the full range of benefits of In Review and how to opt in, or see the In Review platform for yourself here.
Articles
-
-
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
-
Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer’s and non-Alzheimer’s dementia
-
In vivo staging of frontotemporal lobar degeneration TDP-43 type C pathology
-
Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer’s disease after traumatic brain injury
-
Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice
-
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
-
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
-
Cerebral microbleeds: overview and implications in cognitive impairment
-
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
Aims and scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Published Thematic Series
Alzheimer's blogs from BMC
Advertisement
Affiliated with
-
Alzheimer's Research & Therapy is affiliated with Alzheimer's Disease International (ADI).
Annual Journal Metrics
-
Speed
56 days to first decision for reviewed manuscripts only
32 days to first decision for all manuscripts
128 days from submission to acceptance
25 days from acceptance to publication
Citation Impact
6.142 - 2-year Impact Factor
7.072 - 5-year Impact Factor
1.601 - Source Normalized Impact per Paper (SNIP)
2.404 - SCImago Journal Rank (SJR)
Usage
657,918 downloads
1,172 Altmetric mentions
Advertisement
